Primary aldosteronism
Conditions
Interventions
spironolactone
esaxerenone
Sponsors
Tokyo Women's Medical University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who have been diagnosed with primary aldosteronism and wished to receive medication
Exclusion criteria
Exclusion criteria: Patients with secondary hypertension (endocrine hypertension, renovascular hypertension) without primary aldosteronism Patients with essential hypertension Subclinical Cushing syndrome patients Patients with moderate or more impaired renal function (eGFR <30 mL / min / 1.73m2) Diabetic patients with microalbuminuria or proteinuria Serum K value 5.0 mEq / L or more Pituitary hypofunction / hypogonadism patients Patients who have taken MR antagonists in recent 8 weeks Patients with embedded metal parts such as pacemakers Momentum (AES) 1800 METs min / week or more Other patients who are deemed inappropriate by the study director
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in muscle mass before and after treatment with spironolactone and esaxerenone | — |
Countries
Japan
Contacts
Public ContactToru Ishikawa
Tokyo Women's Medical University Hospital department of endocrinology and hypertension
Outcome results
None listed